Please try another search
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.
Name | Age | Since | Title |
---|---|---|---|
Shyam Sunder Bhartia | 69 | 1978 | Chairman |
Hari Shanker Bhartia | 67 | 1982 | Co-Chairman |
Arvind Chokhany | 51 | 2021 | Group CFO & Whole-Time Director |
Arjun Shanker Bhartia | 36 | 2017 | Joint MD & Director |
Priyavrat Bhartia | 47 | 2017 | MD & Director |
Jinang Pratap Parekh | 42 | 2023 | Whole-Time Director |
Sushil Kumar Roongta | 74 | 2017 | Independent Non-Executive Director |
Arun Seth | 73 | 2018 | Independent Non-Executive Director |
Vivek Mehra | 67 | 2017 | Independent Non-Executive Director |
Shirish Gundopant Belapure | 71 | 2023 | Additional Independent Non-Executive Director |
Shivpriya Nanda | 60 | 2024 | Independent Director |
Harsh Mahajan | 65 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review